24
B i o T O P i c s 4 2 _
B i o T O P R e p o r t 2 0 1 1
caprotec bioanalytics GmbH
caprotec bioanalytics GmbH has devel-
oped a ground-breaking, proprietary
tech nology to reduce the complexity of
protein mixtures in a targeted and
directed manner.
Founded in 2006 by scientist and entre-
preneur Prof. Dr. Hubert Köster, founder of
Sequenom Inc. and Biosyntec, caprotec
raised approx. 9 million $ in 2007 and 5
million $ in 2010. Caprotec is operational
in Berlin Adlershof since the beginning
of 2008 and currently has 30 employees.
caprotec’s Capture Compound Mass Spec -
trometry (CCMS) Technology is based on
multifunctional small molecules that are
used to target, capture, and isolate pro-
teins based on their functionality. The
company is commercializing the CCMS
technology as kits for research applica-
tions and in the form of collaborations
for drug development.
In collaborations for drug development
caprotec is using small molecule drugs
or drug candidates to establish a profile
of proteins that interact with the specific
small molecule. The profile can be used
to elucidate the mode of action of drugs
and drug candidates and also to discover
off-target proteins that are responsible
for unwanted side effects, e. g. liver
toxicity.
Address
caprotec bioanalytics GmbH
Volmerstraße 5
12489 Berlin · Germany
Contact
Dr. Christian Jurinke
Director, Product Management
Phone +49 30 63 92 3992
christian.jurinke@caprotec.com
www.caprotec.com
caproKit™ for the characterization of
staurosporine binding protein kinases
Glycotope GmbH
Glycotope has developed a unique and regu-
latory approved platform technology for the
development and production of NBEs and
improved second generation biopharmaceu-
ticals / BioBetters. This toolbox of human cell
lines allows the manifold improvement of
key clinical properties (such as activity, avail-
ability, immunogenicity) for both antibodies
and non-Ab proteins via targeted alteration
of the glycosylation. With excellent produc-
tion features, GlycoExpress is also the base of
Glycotope’s current late-stage pipeline of 4
therapeutic antibodies – two of which have
entered the clinic in 2009 and 2010 with the
third to follow in Q2/2011 – and a non-AB
protein-hormone scheduled to initiate clini-
cal trials in H2/2011.
GlycoExpress
p
Toolbox of glycoengineered human cell
lines
p
Fully human & optimized glycosylation
p
Highly improved bioactivity,
bioavailability & immunogenicity
p
Screening and high yield production
system
p
Permits new patent protection of
products
Pipeline of GlycoOptimized Products
p
Proprietary NBEs & improved second
generation BioBetter antibody and
non-antibody products
Via Glycotope Biotechnology
p
GMP-Production
of biologics
p
Fill & Finish of API and drug
Address
Glycotope GmbH
Robert-Roessle-Strasse 10
13125 Berlin · Germany
Phone +49 30 94892600
Fax
+49 30 94892609
info@glycotope.com
www.glycotope.com
25
B i o T O P i c s 4 2 _
B i o T O P R e p o r t 2 0 1 1
SILENCE Therapeutics AG is the leading
RNAi therapeutics company in Europe.
The Company has developed novel, pro-
prietary short interfering RNA (
siRNA)
molecules called
AtuRNAi and proprietary
systemic delivery systems for siRNA.
Strong IP Position
SILENCE’s strong IP position is based on a
broad portfolio of patents issued in the
US, Europe and other territories.
Validating Pharma Partnerships
SILENCE has established validating part-
nerships with
AstraZeneca ($15m upfront
payment & equity, $400m milestone
payments),
Pfizer/Quark ($95m mile-
stone payments incl. upfront) &
Dainip-
pon Sumitomo (delivery collaboration)
and
Novartis/Quark ($80m milestone
payments incl. upfront).
Four Clinical AtuRNAi Programs
Out of 11 clinical siRNA programs world-
wide as of April 2010 there are
4 clinical
programs (see table) with SILENCE’s AtuR-
NAi molecules. These are SILENCE’s inter-
nal lead program
Atu027 and three clini-
cal study programs conducted by SILENCE’s
partners Pfizer and Quark. This underlines
SILENCE’s leadership in the field of siRNA
therapeutics.
Internal Lead Program
SILENCE’s internal lead program
Atu027
is currently in a
Phase I clinical study
recruiting patients with advanced gastro-
intestinal, lung and other solid cancer (21
patients enrolled as of February 2011).
Recent Corporate Highlights
p
November 10, 2010 Landmark pub-
lication in Clinical Cancer Research
demonstrating the ability of Silence’s
siRNA drug candidate, Atu027, to
prevent the formation of pulmonary
metastasis in various animal models
of cancer metastasis.
p
August 19, 2010 Novartis takes an
option from Quark Pharma (“Quark”)
to obtain an exclusive worldwide
license to develop and commercialise
QPI-1002, a p53 temporary inhibi-
tor siRNA drug which incorporates
Silence’s AtuRNAi technology ($80mil-
lion milestone payments for Silence).
p
July 14, 2010 Extension of the
research collaboration and license
agreement with AstraZeneca which
started in 2007. Silence and Astra-
Zeneca are jointly collaborating on
the identification and optimization of
five novel siRNA therapeutic molecules
addressing respiratory and oncology
indications.
p
May-October 2010 Issuance of various
patents by the United States Patent
and Trademark Office and the Euro-
pean Patent Office.
p
April 21, 2010 Extension of the siRNA
delivery collaboration with AstraZen-
eca which started in 2008. Under this
collaboration a number of Silence’s
proprietary lipid delivery and tar-
geting technologies are leveraged to
develop new and enhanced delivery
approaches for siRNAi therapeutics.
p
March 30, 2010 Expansion of the siRNA
delivery collaboration with Dainippon
Sumitomo Pharma which started in
2009 in order to examine additional
disease targets.
p
January 5, 2010 Merger with US based
Intradigm Corporation - The enlarged
company now possesses multiple RNAi
discovery, development and delivery
technologies, an advancing internal
and partnered product pipeline and
a broad portfolio of intellectual prop-
erty.
SILENCE Therapeutics AG, Berlin, is listed
through its holding company SILENCE
Therapeutics plc, London, at the Alterna-
tive Investments Market (AIM) of the Lon-
don Stock Exchange.
Silence Therapeutics AG
Address
Silence Therapeutics AG
Robert-Rössle-Straße 10
13125 Berlin · Germany
Contact
Thomas Christély
Chief Executive Officer
Dr. Klaus Giese
Chief Scientific Officer
Dr. Jörg Kaufmann
VP Research
Phone +49 30 9489 2800
Fax
+49 30 9489 2801
www.silence-therapeutics.de
info@silence-therapeutics.com
Overview of AtuRNAi Programs
Products
Indications
Partners
Target
Delivery
Preclinical
Phase I
Phase II
Target Tissue/ Organ
PF-4523655 Age-related Macular Degeneration
Quark/Pfizer
RTP-801 (REDD1)
Naked siRNA
Local Delivery to the Eye
QPI-1002
Prevention of Delayed Graft Function
Quark/Novartis
p53
Naked siRNA
Systemic Delivery to the Kidney
QPI-1002
Acute Kidney Injury
Quark
p53
Naked siRNA
Systemic Delivery to the Kidney
Atu027
Solid Tumors (anti-metastatic)
Internal
PKN3
AtuPLEX
Systemic Delivery to Tumor Endothelium
Atu111
Acute Lung Injury
Internal
Ang-2
DACC
Systemic Delivery to Lung Endothelium
Atu134
Solid Tumors
Internal
CD31
AtuPLEX
Systemic Delivery to Tumor Endothelium
Atu150
Solid Tumors
Internal
p110
AtuPLEX
Systemic Delivery to Tumor Endothelium